KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Total Current Liabilities (2018 - 2025)

Vir Biotechnology (VIR) has disclosed Total Current Liabilities for 8 consecutive years, with $92.8 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities fell 22.44% to $92.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $92.8 million through Dec 2025, down 22.44% year-over-year, with the annual reading at $92.8 million for FY2025, 22.44% down from the prior year.
  • Total Current Liabilities hit $92.8 million in Q4 2025 for Vir Biotechnology, up from $75.2 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $702.4 million in Q1 2022 to a low of $75.2 million in Q3 2025.
  • Historically, Total Current Liabilities has averaged $248.5 million across 5 years, with a median of $170.2 million in 2023.
  • Biggest five-year swings in Total Current Liabilities: soared 540.29% in 2021 and later crashed 80.62% in 2024.
  • Year by year, Total Current Liabilities stood at $341.2 million in 2021, then skyrocketed by 49.76% to $511.0 million in 2022, then tumbled by 65.68% to $175.4 million in 2023, then tumbled by 31.78% to $119.7 million in 2024, then dropped by 22.44% to $92.8 million in 2025.
  • Business Quant data shows Total Current Liabilities for VIR at $92.8 million in Q4 2025, $75.2 million in Q3 2025, and $105.0 million in Q2 2025.